Why the study?
Does KBT-3022 inhibit platelet aggregation compared to acetylsalicylic acid in preclinical models?
Does KBT-3022 inhibit platelet aggregation compared to acetylsalicylic acid in preclinical models?
KBT-3022 is a potent inhibitor of platelet activation with weaker gastrointestinal side-effects compared to acetylsalicylic acid in preclinical models.
No takes yet. Share an insight, caveat, or question.
Should not alter antiplatelet practice; leaves open translation of 100-fold potency to human efficacy and safety.
Yokota et al. (1995) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: